NASDAQ: VRCA - Verrica Pharmaceuticals Inc.

Rentabilité sur six mois: -63.38%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Verrica Pharmaceuticals Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

plus de détails
It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2018-06-15
ISIN US92511W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.verrica.com
Цена ао 0.445
Changement de prix par jour: +0.0181% (0.5529)
Changement de prix par semaine: -4.49% (0.579)
Changement de prix par mois: +2.98% (0.537)
Changement de prix sur 3 mois: -15.7% (0.656)
Changement de prix sur six mois: -63.38% (1.51)
Changement de prix par an: -92.1% (7)
Evolution du prix sur 3 ans: -93.14% (8.06)
Evolution du prix sur 5 ans: -92.64% (7.51)
Evolution des prix depuis le début de l'année: -18.2% (0.676)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 57.52 1
P/BV 14.91 1
P/E 0 0
EV/EBITDA -4.34 0
Total: 2.75

Efficacité

Nom Signification Grade
ROA, % -82.1 0
ROE, % -338.99 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.6985 10
Total: 8.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -57.3 0
Rentabilité Ebitda, % 106.63 10
Rentabilité EPS, % 40.72 6
Total: 6.2
Plus de détails

Établissements Volume Partager, %
Perceptive Advisors LLC 5038983 11.98
Avoro Capital Advisors LLC 2954064 7.02
FMR, LLC 1504716 3.58
Vanguard Group Inc 1226858 2.92
Blackrock Inc. 1051050 2.5
Geode Capital Management, LLC 416790 0.99
State Street Corporation 382743 0.91
Caligan Partners, LP 259593 0.62
Northern Trust Corporation 187478 0.45
Boxer Capital, LLC 166955 0.4



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Ted White President, CEO & Director 772.77k 1965 (60 années)
Dr. Gary Goldenberg M.D. Chief Medical Officer 553.03k 1977 (48 années)
Mr. P. Terence Kohler Chief Financial Officer N/A
Mr. Christopher G. Hayes Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel N/A 1964 (61 année)
Mr. Eugene Scavola Executive Vice President of Technical Operations N/A
Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Development N/A

Adresse: United States, West Chester. PA, 44 West Gay Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.verrica.com